Advancing science for people living with HER2-positive biliary tract cancer – Jazz Pharmaceuticals

Jazz Pharmaceuticals shared a post on LinkedIn:

“Biliary tract cancer (BTC) is a relatively rare cancer and is often not diagnosed until an advanced stage. HER2-expressing cancers, like BTC, are just one area where we have reinforced our commitment to science, by helping address the unmet needs within this patient community.

This Rare Cancer Day, learn how we’re working to advance treatment options for BTC and enhance patient support by partnering with the oncology community.”

Source: Jazz Pharmaceuticals/LinkedIn